Antibody-based CCR5 blockade protects Macaques from mucosal SHIV transmission

In the absence of a prophylactic vaccine, the use of antiretroviral therapy (ART) as pre-exposure prophylaxis (PrEP) to prevent HIV acquisition by uninfected individuals is a promising approach to slowing the epidemic, but its efficacy is hampered by incomplete patient adherence and ART-resistant va...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Nature communications 2021-06, Vol.12 (1), p.3343-3343, Article 3343
Hauptverfasser: Chang, Xiao L., Webb, Gabriela M., Wu, Helen L., Greene, Justin M., Abdulhaqq, Shaheed, Bateman, Katherine B., Reed, Jason S., Pessoa, Cleiton, Weber, Whitney C., Maier, Nicholas, Chew, Glen M., Gilbride, Roxanne M., Gao, Lina, Agnor, Rebecca, Giobbi, Travis, Torgerson, Jeffrey, Siess, Don, Burnett, Nicole, Fischer, Miranda, Shiel, Oriene, Moats, Cassandra, Patterson, Bruce, Dhody, Kush, Kelly, Scott, Pourhassan, Nader, Magnani, Diogo M., Smedley, Jeremy, Bimber, Benjamin N., Haigwood, Nancy L., Hansen, Scott G., Brown, Timothy R., Ndhlovu, Lishomwa C., Sacha, Jonah B.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:In the absence of a prophylactic vaccine, the use of antiretroviral therapy (ART) as pre-exposure prophylaxis (PrEP) to prevent HIV acquisition by uninfected individuals is a promising approach to slowing the epidemic, but its efficacy is hampered by incomplete patient adherence and ART-resistant variants. Here, we report that competitive inhibition of HIV Env-CCR5 binding via the CCR5-specific antibody Leronlimab protects rhesus macaques against infection following repeated intrarectal challenges of CCR5-tropic SHIV SF162P3 . Injection of Leronlimab weekly at 10 mg/kg provides significant but partial protection, while biweekly 50 mg/kg provides complete protection from SHIV acquisition. Tissue biopsies from protected macaques post challenge show complete CCR5 receptor occupancy and an absence of viral nucleic acids. After Leronlimab washout, protected macaques remain aviremic, and adoptive transfer of hematologic cells into naïve macaques does not transmit viral infection. These data identify CCR5 blockade with Leronlimab as a promising approach to HIV prophylaxis and support initiation of clinical trials. CCR5 is a co-receptor for many transmitted HIV strains. Here, the authors show that biweekly injection of the CCR5-specific antibody Leronlimab protects rhesus macaques against infection following repeated intrarectal challenges of a CCR5-tropic SHIV.
ISSN:2041-1723
2041-1723
DOI:10.1038/s41467-021-23697-6